SynthesisFrontiers in medicine2025
The prognostic role of maximum tumor dissemination derived by PET/CT in oncological diseases: a systematic review.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic value of lesion dissemination onQuantitative imaging in medicine and surgery · 2026Article
- The predictive and prognostic role of baseline 2-[18F]FDG PET/CT volumetric and dissemination features in classical Hodgkin lymphoma.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Maximum tumor dissemination (Dmax) measured by positron-emission tomography/computed tomography (PET/CT) is a semiquantitative parameter recently introduced with potential prognostic role in several oncological diseases. It is defined as a three-dimensional feature that represents the maximal distance between the two farthest hypermetabolic PET lesions. The aim of our systematic review is to investigate the effective role of Dmax in the management of oncological patients. Methods: The current systematic review was carried out following a preset protocol, and the "Preferred Reporting Items for a Systematic Review and Meta-Analysis" served as a guideline for its development. A comprehensive search of the PubMed/MEDLINE, Embase and Cochrane library databases was conducted until August 2025. Results: A total of 37 studies were included in our research. Lymphoma was the most frequent cancer investigated, followed by prostate cancer, lung cancer and breast cancer. Despite their heterogeneity, most studies showed a significant prognostic role of Dmax in predicting overall survival (OS) and progression free survival (PFS). The combination of Dmax with other PET features, especially MTV, seemed to be useful to stratify patients risk of relapse and/or death. Conclusions: Despite several limitations affecting this analysis, especially related to the heterogeneity of the studies included, PET/CT seems to have a prognostic impact in several oncological diseases, especially in lymphoma. However, few methodological issues still need to be solved before we can implement Dmax in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.